Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors

Regional differences in SARS-CoV-2 variants may affect treatment outcome. Here, the authors show that near-sourced convalescent plasma has higher efficacy, as defined by death within 30 days of transfusion, than plasma sourced more than 150 miles away.

Guardado en:
Detalles Bibliográficos
Autores principales: Katie L. Kunze, Patrick W. Johnson, Noud van Helmond, Jonathon W. Senefeld, Molly M. Petersen, Stephen A. Klassen, Chad C. Wiggins, Allan M. Klompas, Katelyn A. Bruno, John R. Mills, Elitza S. Theel, Matthew R. Buras, Michael A. Golafshar, Matthew A. Sexton, Juan C. Diaz Soto, Sarah E. Baker, John R. A. Shepherd, Nicole C. Verdun, Peter Marks, Nigel S. Paneth, DeLisa Fairweather, R. Scott Wright, Camille M. van Buskirk, Jeffrey L. Winters, James R. Stubbs, Katherine A. Senese, Michaela C. Pletsch, Zachary A. Buchholtz, Robert F. Rea, Vitaly Herasevich, Emily R. Whelan, Andrew J. Clayburn, Kathryn F. Larson, Juan G. Ripoll, Kylie J. Andersen, Elizabeth R. Lesser, Matthew N. P. Vogt, Joshua J. Dennis, Riley J. Regimbal, Philippe R. Bauer, Janis E. Blair, Arturo Casadevall, Rickey E. Carter, Michael J. Joyner
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Q
Acceso en línea:https://doaj.org/article/b4c2e18825314c909846a2c6aed3901d
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Regional differences in SARS-CoV-2 variants may affect treatment outcome. Here, the authors show that near-sourced convalescent plasma has higher efficacy, as defined by death within 30 days of transfusion, than plasma sourced more than 150 miles away.